The arrival of a weight-loss tablet reframes a comparison many people had already been making. Wegovy versus Mounjaro used to be a contest between two weekly injections; now the Wegovy side of the question includes a daily pill, and for needle-averse people that changes the calculation entirely. This article compares the Wegovy pill specifically with Mounjaro: different molecules, different routes, different routines, and a decision that is more personal than the headline numbers suggest. For the injection-versus-injection comparison, see our separate Wegovy vs Mounjaro guide.
Two different medicines, not two versions of one
The Wegovy pill contains semaglutide, which mimics one gut hormone, GLP-1, to reduce appetite and slow stomach emptying. Mounjaro contains tirzepatide, which acts on two receptors, GLP-1 and GIP, a design that appears to strengthen the effect on appetite and metabolism. Both are prescription-only weight-management medicines with staged dose escalation and the same broad eligibility criteria. But they are distinct molecules with separate evidence bases, so this is a genuine choice between treatments, not between formats of the same treatment.
What the trials show
Read side by side with the usual caution about comparing separate trials, the numbers favour Mounjaro on raw effect. Tirzepatide's main trial produced average weight loss up to around 21% of body weight at the highest dose over 72 weeks, and a head-to-head trial against the semaglutide injection confirmed a meaningful advantage. The oral semaglutide trial produced around 15% over 68 weeks, in the same territory as the semaglutide injection. All of these are strong results by any historical standard, and individual variation within each trial dwarfs the average gap between them: plenty of people respond better to semaglutide than the averages predict, and some tolerate one medicine far better than the other, which in practice decides the outcome.
The routine question: daily tablet vs weekly pen
This is where the two could not be more different. Mounjaro asks for one self-injection a week, any time of day, with or without food, using a simple pre-filled pen; its practical demands are close to zero once the first injection is behind you. The Wegovy pill asks for a daily commitment with conditions: empty stomach on waking, a small sip of water, tablet swallowed whole, then a 30-minute wait before food, drink or other medicines. For people with steady mornings who dislike needles, that trade is easy. For people with chaotic mornings and no needle anxiety, the pen is objectively less to get wrong. Be honest about which failure mode is more likely for you, because missed and mistimed doses, not trial averages, are what separate real-world results.
Side effects and safety
The profiles are more alike than different: nausea, constipation or diarrhoea and reduced appetite dominate both, concentrated around dose increases and usually settling with time. Mounjaro adds the possibility of injection-site reactions; the pill cannot cause those but confronts your stomach daily rather than weekly, which some people feel and most do not. Both share the uncommon serious risks of the drug class, pancreatitis and gallbladder disease among them, both are unsuitable in pregnancy, and both need care alongside certain diabetes medicines. Nothing in the safety picture decisively separates them for a typical eligible adult; personal tolerability, which cannot be predicted in advance, often ends up mattering more than anything on paper.
How a sensible decision gets made
Start with the deal-breakers: if injections are simply not going to happen, the pill wins by default and its trial results are more than strong enough to justify it. If maximum average effect is the priority and needles are no obstacle, Mounjaro has the stronger numbers. Between those poles, think in terms of fit: your mornings, your travel patterns, your other medicines and how they sequence around an empty-stomach window, and your history with daily-medication adherence. Availability and supply also fluctuate for all of these medicines, which can settle the question in practice. And remember the decision is reversible: people switch between treatments under clinical guidance when response or tolerability disappoints, so the first choice is a starting point, not a verdict. An assessment with a prescriber who can see your full history is where this comparison becomes a recommendation.
Whichever you land on, the fundamentals are shared: gradual dose escalation, digestive side effects that usually pass, results that build over months, and a medicine that works best alongside eating and activity changes rather than instead of them. Our complete guide to the Wegovy pill covers the tablet in depth if that is the direction you are leaning.
Practicalities that tip real decisions
Beyond the headline trade-offs, a few practical details often settle the choice in one direction or the other. Storage and travel favour the tablet: Mounjaro pens need refrigeration before first use and some planning on long trips, while a blister pack goes anywhere. Other medicines favour the pen: the tablet's empty-stomach window forces morning sequencing with anything else you take, which matters for strict-timing medicines such as levothyroxine, whereas the weekly injection interacts with your schedule hardly at all. Supply favours flexibility: availability of all weight-loss medicines has fluctuated since launch, and being open to either format under clinical guidance means a shortage in one need not interrupt treatment. And discretion cuts both ways: some people prefer a tablet nobody notices, others prefer one private weekly moment to a daily ritual housemates can observe. None of these is decisive alone; stacked against your actual life, they usually point clearly.
